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Abstract
Background: Recent papers have suggested that expanded combination antiretroviral treatment (cART) through
lower viral load may be a strategy to reduce HIV transmission at a population level. We assessed calendar trends in
detectable viral load in patients recruited to the Australian HIV Observational Database who were receiving cART.
Methods: Patients were included in analyses if they had started cART (defined as three or more antiretrovirals) and
had at least one viral load assessment after 1 January 1997. We analyzed detectable viral load (>400 copies/ml) in
the first and second six months of each calendar year while receiving cART. Repeated measures logistic regression
methods were used to account for within and between patient variability. Rates of detectable viral load were
predicted allowing for patients lost to follow up.
Results: Analyses were based on 2439 patients and 31,339 viral load assessments between 1 January 1997 and
31 March 2009. Observed detectable viral load in patients receiving cART declined to 5.3% in the first half of 2009.
Predicted detectable viral load based on multivariate models, allowing for patient loss to follow up, also declined
over time, but at higher levels, to 13.8% in 2009.
Conclusions: Predicted detectable viral load in Australian HIV Observational Database patients receiving cART
declined over calendar time, albeit at higher levels than observed. However, over this period, HIV diagnoses and
estimated HIV incidence increased in Australia.
Background
There has been much interest recently in the role that
combination antiretroviral treatment (cART) might have
in decreasing HIV transmission at a population level.
A reduced HIV viral load as a consequence of cART
appears to reduce the risk of heterosexual HIV trans-
mission [1-3]. At a community level, lower rates of HIV
diagnosis in San Francisco and British Columbia have
accompanied lower viral loads in HIV-infected people
undergoing viral load tests [4,5], and in Taiwan, rapid
expansion of cART was associated with a 50% reduction
in new HIV diagnoses [6].
Despite biological plausibility and the observational
results, mathematical modelling studies have had incon-
sistent conclusions. Some studies have suggested that
early HIV diagnosis and widespread cART could reduce
HIV transmission at a population level [7,8], while
others have suggested that relatively small changes in
sexual risk behaviour could overwhelm any benefits of
cART [9-11]. A key parameter in these mathematical
modelling studies is the effect of cART on HIV viral
load levels, with parameter estimates usually derived
from cohort studies. Such parameter estimates from
cohort studies are, however, often confounded with pro-
blems with missing data and patient loss to follow up.
The objective of this paper is to estimate the propor-
tions of patients with detectable HIV viral load by calen-
dar year in patients receiving cART in the Australian
HIV Observational Database (AHOD), allowing for
patient covariates and differential follow-up patterns.
Methods
Analyses were based on patients recruited to AHOD.
Detailed methods have been described previously [12],
but briefly, AHOD is an observational cohort study of
HIV-infected patients seen at 27 clinical sites around
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every six months for aggregation, quality control and
analysis. Core data variables include: sex; date of birth;
date of most recent visit; HIV exposure; hepatitis B
virus (HBV) surface antigen status; hepatitis C virus
(HCV) antibody status; CD4 and CD8 counts; HIV viral
load; antiretroviral treatment data; AIDS-defining ill-
nesses; and date and cause of death.
Ethics approval was obtained from the University of
New South Wales Human Research Ethics Committee
and all other relevant institutional review boards, and
written informed consent was obtained from all patients.
Patients were included in this analysis if they had
started cART (defined as three or more antiretrovirals),
and had at least one viral load assessment after 1
January 1997. Using an intention-to-treat approach,
patients were considered to remain on cART if they
reverted to mono or double therapy. No account was
taken of changes to the antiretrovirals received.
Complete treatment interruptions of more than 14 days
were excluded from analyses. Any viral load tests prior
to cART were also excluded. A second sensitivity analy-
sis was limited to patient prospective follow up.
The endpoint analyzed was detectable viral load
(defined as >400 copies/ml) in the first and second six
months of each calendar year while receiving cART.
Detectable viral load was defined as >400 copies/ml as
follow up included periods when more sensitive viral
load assays were not available. If a patient had multiple
viral loads in a six-month period, then the viral load clo-
sest to the middle of the period was selected.
The following covariates were considered: age at base-
line (<30, 30-39, 40-49, 50+ years); sex; HIV exposure
(men who have sex with men, MSM + injecting drug
user, IDU, heterosexual, other/unknown); AIDS prior to
first cART; mono or duo antiretroviral treatment prior
to first cART; HCV antibody (no/not tested, ever posi-
tive); HBV surface antigen (no/not tested, ever positive);
viral load prior to first cART (0 to 365 days prior -
<400, >400 copies/ml, missing); CD4 count prior to first
cART (0 to 365 days prior - <100, 100-199, 200-349,
350-499, 500+ cells/mm
3, missing); viral load in previous
six-month period, including viral loads while not receiv-
ing antiretrovirals - if a viral load was missing, then the
previous viral load was carried forward (<400, 400-
10,000, 10,000+, missing); current CD4 count, including
CD4 counts while not receiving ARVs - if a CD4 was
missing, then the previous CD4 was carried forward
(<100, 100-199, 200-349, 350-499, 500+); year first
received cART (1993-96, 1997-99, 2000-2002, 2003+;
this categorization was based on a preliminary analysis
that looked at each year separately, with years of similar
risk grouped together); year first HIV diagnosis (< =
1989, 1990-94, 1995-99, 2000+, not known); and time
since first cART (0-9 months, 9-18 months, 18+
months).
The time since first cART covariate was not modelled
in more detail beyond the early period because this
would fit to patients who survive and had extended fol-
low up. This could introduce a serious bias into the pre-
dicted rates of detectable viral load.
Statistical methods
Repeated measures logistic regression, with generalized
estimating equations methodology, was used to account
for within and between patient variability. An exchange-
able variance structure was assumed, but robust var-
iances calculated, which are robust to incorrect assumed
variance structure. Maximum likelihood random effects
models were also fitted, and found similar covariates to
be significant.
Initially, all covariates were included in the models.
A backward stepwise approach was then used to reduce
to a parsimonious set of statistically significant (2p <
0.05) covariates. Covariates were also excluded if there
appeared to be collinearity problems (for example, asso-
ciations appearing the wrong way in multivariate models).
Predicted rates of detectable viral load
The statistical models were used to make three sets of
predictions for each six-month calendar period, and pre-
dictions compared with observed rates of detectable
viral load. The probability of detectable viral load was
predicted for the following three scenarios:
1. All patients included in the predictions, including
all patients who were lost to follow up, who had
missing values, or who died. This estimates the pro-
portions of patients with detectable viral load if they
had all survived and remained on cART to the
appropriate time point
2. All patients included in the predictions, but
excluding patients who died from the time of death
3. Limiting predictions to patients who had a viral
load test result, so predictions fitted to the analyzed
data.
Scenarios 1 and 3 can be thought of as likely upper
and lower limits on estimates of the proportions of
detectable viral load. Scenario 1, which includes all
patients who are lost to follow up, who cease cART or
w h od i e ,w o u l db ea nu p p e rl i m i t .S c e n a r i o3 ,w h i c h
predicts based only on the analyses data, would be a
lower limit as these are patients who remain in follow
up and so would generally have a better outcome. Sce-
nario 2 was expected to lie within these two limits.
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A total of 2439 patients were eligible for inclusion in the
analysis. The median number of viral loads analyzed for
each patient was 13 (interquartile range 7 to 19). A total
o f6 5 4p a t i e n t s( 4 . 7p e r1 0 0p e r s o ny e a r s )w e r el o s tt o
follow up (defined as more than 12 months without a
clinic visit) and 194 patients died (1.4 per 100 person
years). Patient characteristics at first cART are summar-
ized by year of first cART in Table 1. Patients who first
received cART in the 1990s were more likely to have
been diagnosed earlier with HIV, were slightly younger,
and were slightly more likely to have been infected with
HIV through male-to-male sex. Patients who first
received cART in 1993-96 were much more likely to
have previously received mono or duo ART than those
who initiated cART in later time periods, and also
initiated cART at lower CD4 counts and with more
prior AIDS illnesses. Patients who initiated cART in
2000 or later were more likely to report heterosexual
contact as their route of HIV infection. HCV and HBV
coinfection appeared less common in patients who first
received cART in 2003 or later.
Table 1 Patient characteristics at first cART by year of first cART
Year of first cART
1993-96 1997-99 2000-02 2003+
(N = 771) (N = 934) (N = 280) (N = 454)
Sex M 735 (95%) 878 (94%) 258 (92%) 424 (93%)
F 36 (5%) 56 (6%) 22 (8%) 30 (7%)
Age (years) Mean (SD) 39 (8.9) 39 (9.9) 40 (10.0) 43 (10.2)
Median (IQR) 37 (32,45) 37 (31,45) 39 (33,46) 42 (36,49)
HIV exposure MSM 641 (83%) 728 (78%) 195 (70%) 336 (74%)
MSM+IDU 31 (4%) 40 (4%) 16 (6%) 9 (2%)
IDU 12 (2%) 34 (4%) 3 (1%) 8 (2%)
Heterosexual 45 (6%) 69 (7%) 44 (16%) 65 (14%)
Other/unknown 42 (5%) 63 (7%) 22 (8%) 36 (8%)
Year first HIV diagnosis < = 1989 334 (43%) 244 (26%) 46 (16%) 36 (8%)
1990-94 313 (41%) 290 (31%) 50 (18%) 42 (9%)
1995-99 119 (15%) 395 (42%) 68 (39%) 67 (15%)
2000+ 0 0 109 (39%) 267 (59%)
Not known 5 (1%) 5 (1%) 7 (3%) 42 (9%)
Prior AIDS No 620 (80%) 808 (87%) 234 (84%) 407 (90%)
Yes 151 (20%) 126 (13%) 46 (16%) 47 (10%)
Prior mono/Double ART No 182 (24%) 632 (68%) 209 (75%) 377 (83%)
Yes 589 (76%) 302 (32%) 71 (25%) 77 (17%)
HCV No/not tested 673 (87%) 822 (88%) 248 (89%) 423 (93%)
Ever positive 98 (13%) 112 (12%) 32 (11%) 31 (7%)
HBV No/not tested 726 (94%) 878 (94%) 263 (94%) 444 (98%)
Ever positive 45 (6%) 56 (6%) 17 (6%) 10 (2%)
Log10 viral load Mean (SD) 4.6 (1.03) 4.5 (1.01) 4.6 (1.11) 4.4 (1.3)
Median (IQR) 4.7 (4.0,5.4) 4.7 (3.9,5.3) 4.9 (4.2,5.4) 4.8 (3.7,5.2)
N missing 409 (53%) 171 (18%) 44 (16%) 60 (13%)
CD4 Count Mean (SD) 247 (180) 356 (241) 331 (259) 332 (238)
Median (IQR) 220 (180,369) 330 (180,487) 283(130,486) 279 (180,429)
N missing 187 (24%) 167 (18%) 41 (15%) 51 (11%)
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Table 2. Factors associated with a greater risk of detect-
able viral load were found to be younger age, prior
mono or duo ART, a detectable previous viral load, a
lower current CD4 count, and the 18-month period
immediately after starting cART. First cART in more
recent calendar times, and more recent reported HIV
diagnosis, were found to be associated with a decreased
risk of detectable viral load.
Observed proportions of detectable viral load in
patients receiving cART, by six-month calendar year
periods, together with model-fitted predicted propor-
tions, are shown for all patients combined in Figure 1.
This shows a strong continuing decrease in the observed
proportion of patients receiving cART with a detectable
viral load, from more than 50% in 1997 and 1998 to
around 7.7% in 2007, 6.3% in 2008, and 5.3% in the first
half of 2009. However, the model-predicted proportions
of detectable viral load are much higher. Under scenario
1, predicting for all patients including those who were
lost to follow up or died, the predicted proportion in
2009 was 16.0%. The predicted proportions for scenarios
2 and 3 were 13.8% and 10.1%, respectively.
Observed and predicted proportions of detectable viral
load by period of first cART are shown in Figure 2.
Across all periods of first cART, there is the same
strong decreasing proportion of detectable viral load
down to around 5-6% in 2009. Perhaps not surprisingly,
the predicted rates are much higher for patients who
first received cART in earlier periods. The predicted
proportions of detectable viral load under scenario 2 in
2009 were 19.4%, 14.9%, 9.8% and 5.7% for the four per-
iods, respectively.
Sensitivity analyses were also performed based on
patient prospective data only. These analyses found the
same covariates to be included in multivariate models,
and gave similar trends in observed and predicted pro-
portions of detectable viral loads (data not presented).
Discussion
The proportion of patients in AHOD with detectable
viral load while receiving cART has been observed to be
decreasing, to around 6% in 2009. These analyses, which
adjust for patient covariates and differential follow up,
suggest that the true proportions of patients in AHOD
receiving cART with detectable viral load in more recent
calendar time periods are higher than the simple
observed proportions. The higher estimated proportion
of patients with detectable viral load in adjusted analyses
Table 2 Predictors of detectable viral load (>400 copies/
ml) - all patients 1997-2009
Odds
ratio
95% CI p
Age at first cART <30 years 1.0
30-39 0.89 (0.77, 1.02) 0.100
40-49 0.80 (0.68, 0.93) 0.005
50+ 0.59 (0.49, 0.71) <0.001
Previous mono/
double ART
No 1.0
Yes 1.33 (1.19, 1.48) <0.001
Previous viral load < = 400
copies/ml
1.0
401-10,000 9.76 (8.79, 10.85) <0.001
10,001+ 8.65 (7.73, 9.67) <0.001
Missing 6.94 (5.76, 6.01) <0.001
Current CD4 <100 cells/
mm
3
1.0
100-199 0.50 (0.42, 0.60) <0.001
200-349 0.33 (0.27, 0.39) <0.001
350-499 0.25 (0.21, 0.30) <0.001
500+ 0.18 (0.15, 0.21) <0.001
Time since first cART >18 months 1.0
0-9 months 1.34 (1.19, 1.49) <0.001
9-18 months 1.98 (1.79, 2.19) <0.001
Year of first cART 1993-96 1.0
1997-99 0.71 (0.63, 0.80) <0.001
2000-02 0.41 (0.33, 0.52) <0.001
2003+ 0.23 (0.18, 0.29) <0.001
Year first HIV
diagnosis
< = 1989 1.0
1990-94 1.07 (0.95, 1.21) 0.247
1995-99 0.81 (0.70, 0.93) 0.003
2000+ 0.89 (0.69, 1.14) 0.365
Not known 0.97 (0.61, 1.56) 0.914
Covariates omitted from the model:CD4 at first cART, sex, viral load at first
cART, prior AIDS, HBV, HCV, HIV exposure.
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Figure 1 AHOD detectable viral load 1997-2009.
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to follow up, and observed proportions should be used
with caution because of this bias.
Under scenario 2 (which includes in predictions
patients with unmeasured viral load or who have
become lost to follow up), but censors patients who
have died, the predicted proportion of patients with
detectable viral load in 2009 was 13.8% compared with
an observed proportion of 6.3%. Although predicted
proportions of detectable viral load were higher than
observed proportions, a consistent finding of our ana-
lyses was that there was no evidence of increasing pro-
portions of patients with detectable viral load, both
overall and by time of first cART. This is reassuring as
it suggests that there is as yet no evidence of cohorts of
HIV-infected patients running out of effective treatment
options.
Our analyses specifically looked at detectable viral load
by calendar time. We performed this analysis, as
opposed to looking at detectable viral load from time of
first cART, because of the recent interest in levels of
community viral load in HIV-infected patients receiving
viral load tests by calendar time, and how this might
impact on HIV transmission at a population level [1-6].
In Australia, as many other countries, population-level
data on rates of detectable viral load in patients receiv-
ing cART are unavailable. AHOD, a large observational
cohort study that includes 15-20% of all patients in Aus-
tralia receiving cART [13], is the best available source of
data on this issue on which to base assumptions for
mathematical models [9-11,14]. As such, analyses of this
type, assessing the effect of differential follow up on
observed viral load levels in AHOD, are important for
developing the most accurate assumptions possible.
Combination ART is publicly funded and freely avail-
able to all HIV-infected patients in Australia. The HIV
epidemic remains very largely (85%) transmitted through
male homosexual sex [15], a well-educated and
informed population. In uninfected homosexual men,
HIV testing was reported to take place at least annually
in around 60% of men in 2006, and this proportion
increased between 1998 and 2006 [16]. The absolute
number of HIV-infected people in Australia receiving
cART has been estimated to have increased between
2000 and 2006, though the proportion of all HIV-
infected people receiving cART was estimated to have
increased only slightly or remained flat [17].
Finally, the analyses presented here suggest that in
HIV-infected men receiving cART, HIV viral load has
continued to decrease through the 2000s, albeit at
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cumstances in Australia would appear to offer the best
hope for cART to have an effect on reducing HIV trans-
mission at a population level. However, over this period,
total HIV diagnoses have increased in Australia, from a
low of 718 new diagnoses in 1999 to around 1000 new
diagnoses annually in 2006-2008 [15].
Mathematical models and back-projections analyses
have both suggested that this reflects a real increase in
HIV incidence in homosexual men [11,18]. If the
decreasing trends in detectable viral load in AHOD
patients receiving cART are representative of all HIV-
infected patients receiving cART in Australia, then this
suggests that in Australia, the likely reduction in HIV
transmission risk in patients receiving cART through
reduced HIV viral load is being counterbalanced by
increasing infection risk due to behavioural changes.
This underscores the importance of continued vigilance
with existing HIV prevention strategies, including symp-
tom awareness, early risk assessment, diagnosis and
referral for care and treatment.
Mathematical modelling has been used to investigate
trends in HIV incidence in Australia. Early models did
suggest a decrease in HIV incidence among homosexual
men during 1996 to 1998 due to the introduction of
widespread cART, but that this was followed in 1998 to
2001 by a slow increase in incidence due to increasing
rates of unprotected anal intercourse with casual part-
ners while use of cART remained fairly stable [10].
More recent modelling suggested that the observed
increase in HIV incidence in homosexual men in some
Australian states might be explained by increasing rates
of other sexually transmissible infections [11]. These
models also estimated that 19% of incident HIV infec-
tions were transmitted from the estimated 3% of HIV-
infected homosexual men in primary HIV infection, and
that 31% of incident HIV infections were transmitted
from the estimated 9% of HIV-infected homosexual
men with undiagnosed infection [14].
A key limitation of our analyses is the extent to which
trends in AHOD are representative of all HIV-infected
people in Australia. AHOD is an observational cohort
study of HIV-infected people attending clinics for their
care, and recruited more patients in the late 1990s and
early 2000s than in recent years. Hence trends in unde-
tectable viral load may not reflect all HIV-infected
patients receiving cART. We did stratify trends by dif-
ferent periods of first cART to try to assess this. AHOD
represents 15-20% of HIV-infected patients receiving
cART, and in terms of key epidemiological characteris-
tics, seems reasonably representative of the wider HIV
epidemic in Australia [13]. However, the estimates of
trends in detectable viral load on cART in AHOD pre-
s e n t e dh e r ea r ed i f f e r e n tt ot h et r u ee s t i m a t e so f
community viral load that are available in other studies
[4,5], but unavailable in Australia. In particular, our
analyses take no account of trends in viral load in
HIV-infected people who are not receiving cART. Gener-
alization of our results to inferences about levels of com-
munity viral load in Australia should be made with
caution.
A further limitation is that AHOD, as with all obser-
vational cohorts, has missing data and some patients
were lost to follow up. While we predicted trends in
detectable viral load adjusted for important covariates
using statistical models that allow for patients lost to
follow up, there may be unmeasured and unmeasurable
confounders that would affect our results. In particular,
it may be that the apparent continuing decline in detect-
able viral load in patients receiving cART, albeit at
higher levels than observed declines, is better inter-
preted as a plateau over the period from the mid-2000s.
Conclusions
Our analyses suggest that in AHOD, true calendar
trends in detectable viral in HIV-infected patients
receiving cART are higher than observed trends when
adjusted for confounding covariates and patients lost to
follow up. Whether these predictions reflect true conti-
nuing decreases, or actually something more of a pla-
teau, we feel is open to interpretation. It is reassuring
that under all models, there was no suggestion of
increasing detectable viral load, either observed or pre-
dicted. The fact that these decreasing trends in detect-
able viral load in patients receiving cART in AHOD
have been accompanied by increases in HIV diagnoses
and estimated HIV incidence suggests that, at least in
Australia, the likely decrease in the risk of transmission
from people receiving cART as a result of reduced HIV
viral load is being counterbalanced by increasing risk of
transmission due to behaviour changes.
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